No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PSTX Poseida Therapeutics
- 2.715
- +0.065+2.45%
Trading Jun 5 11:38 ET
263.24MMarket Cap-2320P/E (TTM)
2.750High2.650Low88.35KVolume2.660Open2.650Pre Close239.18KTurnover0.14%Turnover RatioLossP/E (Static)96.96MShares4.27052wk High3.11P/B174.59MFloat Cap1.54052wk Low--Dividend TTM64.31MShs Float17.620Historical High--Div YieldTTM3.77%Amplitude1.540Historical Low2.707Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
SAN DIEGO, June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments
H.C. Wainwright Maintains Poseida Therapeutics(PSTX.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright analyst Arthur He CFA maintains $Poseida Therapeutics(PSTX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 5
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
Express News | Poseida Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
Piper Sandler Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)
Poseida Therapeutics: A Strong Buy on Robust Pipeline, Strategic Partnerships, and Leadership Enhancements
Comments
$Poseida Therapeutics(PSTX.US$
NEWS
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
NEWS
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
$Poseida Therapeutics(PSTX.US$
NEWS
Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
NEWS
Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
Dr. Rizvi's appointment, with his vast experience in cancer treatments, is a major asset to Poseida Therapeutics. His expertise will be crucial as the company progresses its clinical stage CAR-T portfolio.
2
Poseida Therapeutics' P/S ratio remains modest despite the recent stock price surge. With inferior revenue forecasts and expected revenue decline, it's unlikely for a significant increase in share price in the near future.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg